Biomarkers are key for rare disease drug development……..

A very interesting paper that proposes biomarkers as important ‘end points’ in clinical trials for rare disease drugs.
Rare disease drugsAnd why is this important for genetic skeletal disease…..?

There are currently no effective diagnostic and prognostic biomarkers of early stage cartilage degradation for both common and rare skeletal diseases. Diagnosis of arthritis is currently based on imaging techniques such a radiographs performed well after the onset of symptoms such as pain and stiffness. Early and non-invasive markers of cartilage degeneration will provide an evidence-base for appropriate clinical management regimes.

Furthermore, biomarkers are also a vital requirement in clinical trials. Recent advances in understanding disease mechanisms has led to clinical trails for two rare skeletal disease; hypophosphatasia and achondroplasia. However, lack of a suitable biomarker has had a negative impact on defining end-points for these trials.

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s